3.4.24.82	degradation	abrasion of cartilage aggrecan in rheumatoid arthritis and osteoarthritis	667796	
3.4.24.82	degradation	degradation of cartilage in late-stage Lyme arthritis	-, 667360	
3.4.24.82	degradation	degradation of cartilage proteoglycan (aggrecan) in osteoarthritis and rheumatoid arthritis	669244	
3.4.24.82	medicine	ADAMTS-4 is a key enzyme in osteoarthritis	720093	
3.4.24.82	medicine	design and development for potent and selective inhibitors of ADAMTS-4 and ADAMTS-5, which will be required for chronic osteoarthritis therapy	709044	
3.4.24.82	medicine	full-length ADAMTS4 and its catalytically more active N-terminal 53 kDa autocatalytic fragment both promote B16 melanoma growth and angiogenesis in mice. Overexpression of its catalytically inactive E362A mutant or truncated fragments containing only the C-terminal ancillary domains suppresses melanoma growth and angiogenesis under similar conditions. The single thrombospondin-type 1 repeat domain is essential and sufficient for the antitumorigenic activity of the catalytically inactive ADAMTS4 isoforms. Suppression of tumor growth and angiogenesis in mice is accompanied by a significant increase in tumor cell apoptosis, whereas tumor cell proliferation is not affected	733990	
3.4.24.82	medicine	in synovial fluid of most orthopaedic patients ADAMTS-4 activity is undetectable. ADAMTS-4 ranges from 0 to 2.8 ng/mL in synovial fluid from patients with an injury, 0-4.1 ng/mL in osteoarthritic patients and 4.0-12.3 ng/mL in patients with large effusions	734830	
3.4.24.82	medicine	stop progression of cartilage degradation in osteoarthritis by prevention of aggrecan cleavage via inhibition of aggrecanase-1	696674	
3.4.24.82	medicine	the pattern of ADAMTS4 release observed is clearly different in various forms of ACS. ADAMTS4 shows a weak correlation with high-sensitivity C-reactive protein. However, no significant correlation is found between ADAMTS4 and troponin T in acute coronary syndromes patients	707655	
3.4.24.82	medicine	therapeutic target in osteoarthritis	679302	
3.4.24.82	additional information	neurite extension mediated by the MAP kinase pathway, increased number of primary and secondary neurites	697804